

## **SYNER-G BIOPHARMA GROUP ACQUIRES IMPACT; EXPANDS SERVICES FOR BIOTECH AND PHARMA COMPANIES**

- *The acquisition enables Syner-G to provide deeper, broader expertise to customers*
- *Adds medical writing and regulatory strategy, publishing, and submission to Syner-G's offering*
- *Expands Syner-G's presence in the fast-growing RTP biotech hub*

Boston, MA (February 1, 2022) - Syner-G BioPharma Group ("Syner-G" or the "Company"), a leading provider of Chemistry, Manufacturing, and Controls ("CMC") technical, regulatory, and compliance consulting services to pharmaceutical and biotechnology clients, today announced the acquisition of Impact Pharmaceutical Services ("IMPACT"). Based in Research Triangle Park, NC, IMPACT supports the outsourced medical writing, regulatory strategy, and regulatory publishing and submission needs of biotech and pharma companies from pre-IND through post-marketing of drugs and biologics.

Both Syner-G and IMPACT have demonstrated strong track records of consistent growth and success in providing customized and highly complementary solutions to support the development of quality of life enhancing and lifesaving therapeutics. The combination will allow the companies to provide an even greater depth and breadth of expertise while delivering the highest levels of scientific rigor and customer service.

"This acquisition adds medical writing, overall drug development and regulatory strategy, and regulatory publishing and submission services to Syner-G's capabilities which will allow us to better support our customers as they develop lifesaving and breakthrough therapeutics," stated Prabu Nambiar, Founder and CEO of Syner-G. "The combination brings together two excellent companies with very similar organizational histories, operating philosophies, and corporate cultures."

"We are thrilled to add IMPACT's complementary service offering and excellent team of qualified, experienced, and dedicated employees to Syner-G," added Binesh Prabhakar, Co-Founder and Senior Vice President of Quality Assurance & Compliance of Syner-G. "In addition, the transaction will allow Syner-G to have a significant presence in the RTP area, a fast growing biotech hub."

# PRESS RELEASE



"IMPACT's expertise and experience, gained over more than a decade serving its clients, is a perfect extension of Syner-G's best-in-class CMC capabilities," said Mark Cierpial, Founder and CEO of IMPACT. "We are excited to form this strong partnership and work together to build a leading biopharma services organization."

Financial terms of the transaction, which closed in late December, were not disclosed.

###

## **About Syner-G BioPharma Group**

Based in Boston, MA, Syner-G is a leading provider of customized science and risk-based CMC and regulatory solutions and services, supporting pharmaceutical and biotechnology companies across small molecule, large molecule, and cell and gene therapy products. With its high customer retention, Syner-G oversees all aspects of CMC and regulatory services throughout the drug development process and post-commercialization. For more information, visit [www.synergbiopharma.com](http://www.synergbiopharma.com).

## **About Impact Pharmaceutical Services**

Based in Research Triangle Park, NC, IMPACT specializes in medical writing and quality control, drug development consulting, regulatory affairs, regulatory operations, and project and program management for the pharmaceutical and biotech sector. For more information, visit [www.impactpharma.com](http://www.impactpharma.com).

## **Syner-G BioPharma Group Contact:**

Stephen Cote  
Chief Financial Officer  
(508) 460-9700  
[stephen.cote@synergbiopharma.com](mailto:stephen.cote@synergbiopharma.com)

## **For Media Inquiries:**

Maria Garvey  
Delfino Marketing Communications, Inc.  
(914) 747-1400  
[maria@delfino.com](mailto:maria@delfino.com)